# Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

> **NCT02614508** · PHASE1 · TERMINATED · sponsor: **Emory University** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Buparlisib
- **DRUG:** Ibrutinib
- **BIOLOGICAL:** Ofatumumab

## Key facts

- **NCT ID:** NCT02614508
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614508, "Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02614508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*